Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
Here are three of the most important factors that make the stock of this rare disease biopharmaceutical a great growth pick right now.
Earnings Growth
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for BioMarin is 40.9%, investors should actually focus on the projected growth. The company's EPS is expected to grow 23% this year, crushing the industry average, which calls for EPS growth of 19.7%.
Cash Flow Growth
Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.
Right now, year-over-year cash flow growth for BioMarin is 83.6%, which is higher than many of its peers. In fact, the rate compares to the industry average of -4.7%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 40.1% over the past 3-5 years versus the industry average of 4.1%.
Promising Earnings Estimate Revisions
Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for BioMarin have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month.
Bottom Line
BioMarin has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #1 because of the positive earnings estimate revisions.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination indicates that BioMarin is a potential outperformer and a solid choice for growth investors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Gray Media (GTN) Stock Declines While Market Improves: Some Information for Investors
In the latest close session, Gray Media (GTN) was down 3.31% at $4.97. This move lagged the S&P 500's daily gain of 0.4%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.24%. Shares of the broadcast television company witnessed a gain of 12.97% over the previous month, beating the performance of the Consumer Discretionary sector with its gain of 2.16%, and the S&P 500's gain of 4.61%. The investment community will be closely monitoring the performance of Gray Media in its forthcoming earnings report. The company is scheduled to release its earnings on August 8, 2025. The company is predicted to post an EPS of -$0.34, indicating a 477.78% decline compared to the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.72 per share and revenue of $3.15 billion, indicating changes of -121.43% and -13.67%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Gray Media. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Gray Media currently has a Zacks Rank of #3 (Hold). The Broadcast Radio and Television industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gray Media Inc. (GTN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Archer Aviation Inc. (ACHR) Outpaces Stock Market Gains: What You Should Know
Archer Aviation Inc. (ACHR) closed at $11.21 in the latest trading session, marking a +2% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.4%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.24%. Shares of the company have appreciated by 3.78% over the course of the past month, underperforming the Aerospace sector's gain of 5.88%, and the S&P 500's gain of 4.61%. Investors will be eagerly watching for the performance of Archer Aviation Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.2, indicating a 16.67% growth compared to the equivalent quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.76 per share and a revenue of $11.29 million, indicating changes of +32.74% and 0%, respectively, from the former year. Investors might also notice recent changes to analyst estimates for Archer Aviation Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Archer Aviation Inc. is currently a Zacks Rank #3 (Hold). The Aerospace - Defense industry is part of the Aerospace sector. This group has a Zacks Industry Rank of 85, putting it in the top 35% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Archer Aviation Inc. (ACHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 hours ago
- Yahoo
Sensus Healthcare, Inc. (SRTS) Stock Drops Despite Market Gains: Important Facts to Note
Sensus Healthcare, Inc. (SRTS) closed at $5.51 in the latest trading session, marking a -2.48% move from the prior day. This move lagged the S&P 500's daily gain of 0.4%. At the same time, the Dow added 0.47%, and the tech-heavy Nasdaq gained 0.24%. Coming into today, shares of the company had gained 17.22% in the past month. In that same time, the Medical sector gained 1.19%, while the S&P 500 gained 4.61%. The upcoming earnings release of Sensus Healthcare, Inc. will be of great interest to investors. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $8.8 million, indicating a 4.76% downward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.11 per share and a revenue of $41.95 million, signifying shifts of -73.17% and +0.34%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Sensus Healthcare, Inc. presently features a Zacks Rank of #4 (Sell). Looking at valuation, Sensus Healthcare, Inc. is presently trading at a Forward P/E ratio of 51.36. For comparison, its industry has an average Forward P/E of 23.12, which means Sensus Healthcare, Inc. is trading at a premium to the group. The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 165, finds itself in the bottom 34% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sensus Healthcare, Inc. (SRTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
